Methotrexate May Be More Effective Than Leflunomide for JRA

April 20, 2007 — Methotrexate may be more effective than arava for the communicating of polyarticular juvenile rheumatoid arthritis (JRA), according to the results of a multinational, randomized domain published in the April 21 supply of the New England Volume of Medicinal drug .
“In six-month trials, both methotrexate and sulfasalazine were more effective than vesper in children with juvenile rheumatoid arthritis and had acceptable short-term prophylactic profiles,” write Earl Silverman, MD, from the Educational institution of Toronto in Canada, and colleagues from the Leflunomide in Juvenile Rheumatoid Arthritis Researcher Mathematical group. “In a Jack open-label reflexion of children with polyarticular-course juvenile rheumatoid arthritis, 52% of those receiving leflunomide had a way, even though all patients either had had no way to or were intolerant of methotrexate.”
In a double-dummy blinded engrossment, patients 3 to 17 time of life of age received leflunomide or methotrexate for 16 weeks.
Of 94 patients randomized, 86 completed 16 weeks of management, of whom 70 entered a 32-week blinded wing learning.
The investigators assessed rates of American English Building complex of Rheumatology (ACR) Pediatric 30 percent (ACR Pedi 30) responses and the Percent Status Fact (PII) at criterion and every four weeks for 16 weeks, and then every spot weeks during the improver report.
At week 16, 89% of patients in the methotrexate radical and 68% in the arava building block had an ACR Pedi 30 speech act ( P = .02).
This is a part of article Methotrexate May Be More Effective Than Leflunomide for JRA Taken from "Arava Information" Information Blog